LSM7 homolog, U6 small nuclear RNA and mRNA degradation associatedGenealiases: LDCA · YNL147W
Q-omics provides the consensus-scored LSM7 profile across patient tissues and cancer cell-line models. LSM7 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LSM7 is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, LSM7 protein abundance shows 24,473 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, COAD, and GBM as cancer lineages where LSM7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LSM7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LSM7 survival associations across molecular data types. LSM7 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LSM7 RNA expression–survival associations across cancer types. High LSM7 expression shows unfavorable associations in KIRC, ACC, UVM, UCS and LIHC, but favorable associations in UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LSM7 RNA expression.
This table summarizes LSM7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for LSM7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LSM7 shows higher tumor expression in COAD, BLCA, KIRC, STAD, LIHC and HNSC. The COAD box plot shows higher LSM7 RNA expression in tumor versus normal tissue (log2 FC = +1.867, t-test p < 0.001).
This table shows molecular features associated with LSM7 in patient tissues and cancer cell lines. In patient samples, LSM7 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, LSM7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Lymphoma.
